Overview
- Chai Discovery secured a reported $400 million Series C in mid‑July 2026 that industry coverage says lifts its valuation into the multi‑billion dollar range, with reports varying between $3.4 billion and $3.8 billion.
- The round drew top venture and strategic backers led by Index Ventures and including Kleiner Perkins, Sequoia, OpenAI and returning investors, giving the company deep financial and technical support.
- Chai unveiled its next‑generation Chai‑3 model and says its platform now delivers materially higher experimental 'hit rates' for de novo antibody design compared with legacy methods, building on Chai‑2’s reported roughly 20% hit rate versus historical 0.1% baselines.
- The company already has commercial relationships with large pharmaceutical firms such as Eli Lilly, Pfizer and Novartis and has added senior pharma talent to its board to smooth enterprise adoption and create proprietary data loops.
- If Chai’s lab success scales through clinical validation, the immediate effects may be faster candidate generation and lower early‑stage costs for patients and researchers, and the round also suggests traditional VC and pharma partnerships are driving near‑term investment in AI drug discovery more than crypto‑native models.